Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-l-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery

[Image: see text] The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) exhibits remarkable anticancer efficacy; however, its therapeutic potential is hindered by its toxicity to gastrointestinal (GI) tissues. We recently reported the discovery of DRP-104, a tumor-targeted DON prodrug with excel...

Descripción completa

Detalles Bibliográficos
Autores principales: Novotná, Kateřina, Tenora, Lukáš, Prchalová, Eva, Paule, James, Alt, Jesse, Veeravalli, Vijay, Lam, Jenny, Wu, Ying, Šnajdr, Ivan, Gori, Sadakatali, Mettu, Vijaya Saradhi, Tsukamoto, Takashi, Majer, Pavel, Slusher, Barbara S., Rais, Rana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683027/
https://www.ncbi.nlm.nih.gov/pubmed/37949450
http://dx.doi.org/10.1021/acs.jmedchem.3c01681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683027/
https://www.ncbi.nlm.nih.gov/pubmed/37949450
http://dx.doi.org/10.1021/acs.jmedchem.3c01681

Ejemplares similares